pLenti CMV Puro DEST (w118-1) eGFP Citations (1)
Originally described in: PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia.Aries IM, Bodaar K, Karim SA, Chonghaile TN, Hinze L, Burns MA, Pfirrmann M, Degar J, Landrigan JT, Balbach S, Peirs S, Menten B, Isenhart R, Stevenson KE, Neuberg DS, Devidas M, Loh ML, Hunger SP, Teachey DT, Rabin KR, Winter SS, Dunsmore KP, Wood BL, Silverman LB, Sallan SE, Van Vlierberghe P, Orkin SH, Knoechel B, Letai AG, Gutierrez A J Exp Med. 2018 Nov 7. pii: jem.20180570. doi: 10.1084/jem.20180570. PubMed Journal
Articles Citing pLenti CMV Puro DEST (w118-1) eGFP
| Articles |
|---|
| Patient-derived xenografts and in vitro model show rationale for imatinib mesylate repurposing in HEY1-NCoA2-driven mesenchymal chondrosarcoma. Safaric Tepes P, Segovia D, Jevtic S, Ramirez D, Lyons SK, Sordella R. Lab Invest. 2021 Nov 26. pii: 10.1038/s41374-021-00704-4. doi: 10.1038/s41374-021-00704-4. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.